side-area-logo

About Eloxx

Committed to Treating Rare and
Ultra-Rare Genetic Diseases

Eloxx Pharmaceuticals is a clinical stage company developing first in class therapeutics for the treatment of genetic disease caused by non-sense mutations.

The company is led by a management team experienced in the development of rare disease therapeutics. All of us at Eloxx share the same goal: to bring safe and effective therapies to the children and adults suffering from genetic diseases who need them, as quickly as possible

Management

Dr. Silvia Noiman has over 20 years of experience as an entrepreneur and executive in the biopharmaceuticals industry, including serving as venture partner at Pontifax Venture Capital. Dr. Noiman founded and served as Executive Chairwoman of many of the Pontifax VC portfolio companies, including cCAM Biotherapeutics Ltd, acquired by Merck (NYSE:MRK) in 2015 and Quiet Therapeutics Ltd. She was also founder and Senior Vice President of Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a $500M publicly traded multi-product company (NASDAQ, EPIX). Under Dr. Noiman’s leadership, the company progressed four discovery programs to late stage clinical trials and formed significant big pharma partnerships. Prior to founding Predix, she was engaged in large-scale entrepreneurial activities in the biotech industry in Israel. Dr. Noiman holds a PhD in Molecular Biology from Tel Aviv University and did a post-doc at the Weizmann Institute of Science. Dr. Noiman has published numerous papers and holds several patents.

Dr. Huertas has been active in the pharmaceutical industry for nearly 20 years and is experienced in research, development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas’ last position was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development. Dr. Huertas has extensive experience dealing with and participating in negotiations with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA), and throughout Latin America. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe, and Japan. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

Dr. Huertas has been active in the pharmaceutical industry for nearly 20 years and is experienced in research, development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas’ last position was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development. Dr. Huertas has extensive experience dealing with and participating in negotiations with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA), and throughout Latin America. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe, and Japan. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

Mr. Weaver is a seasoned financial executive with more than 30 years of experience in leading business and financial operations for private and public companies, including financing transactions, strategic planning, investor relations, and business development initiatives. Mr. Weaver has been instrumental in raising more than $900 million in private and public equity and debt financing for both U.S. and international life science companies. Prior to joining Eloxx, Mr. Weaver served as Chief Financial Officer of Prometic Life Sciences, where he led the Company’s global financial team. Previously, Mr. Weaver served as Executive Vice President and Chief Financial Officer of Oryzon Genomics where he managed the Company’s IPO financing. Earlier in his career, Mr. Weaver served as Chief Financial Officer of several other life sciences companies, including Fibrocell Science, Celsion Corp., Poniard Pharmaceuticals, and Sirna Therapeutics. In addition, Mr. Weaver currently serves as a member of the Board of Directors of Egalet Corporation and Atossa Genetics. Mr. Weaver received his M.B.A. from Boston College, a B.S. in accounting from Trinity University, and U.S. CPA certification.

Dr. Pelled brings to Eloxx over 15 years of experience in the biotech industry. Prior to joining Eloxx, he headed the preclinical research and development at Chiasma Pharmaceuticals Ltd. (NASDAQ:CHMA), a drug company that redevelops poorly-absorbed small molecules into oral drugs, and at NiTi Surgical Solutions, a medical device company that focused on implants for gastrointestinal surgery. Prior to NiTi, he was responsible for clinical research and for the developing of new molecules in the medical food company, Enzymotec (NASDAQ:ENZY), where he served as the Director of Clinical Studies and as the CTO. Dr. Pelled has published over 25 original papers in peer-reviewed journals and he holds 15 patents. He received his PhD in Biochemistry from the Weizmann Institute of Science, and obtained BSc and MSc degrees in Chemistry and Clinical Biochemistry from the Tel-Aviv University.

Mr. Chaim Eldar has vast experience in leading business activities worldwide and he practiced Financial and Operations management for approx. 20 years. In his last position, he served as the CFO of a subsidiary of Horizon Pharma (NASDAQ:HZNP), where Chaim managed of all the financial activities, incl. financial statements according to IFRS and to US GAAP standards. Previously, he served as the CFO of the Hong Kong and China subsidiary of Electra Ltd (TLV: ELTR), a global company engaged in the manufacturing and marketing of consumer goods, where he established and managed the financial operations of the firm in China as well as its IT, HR, Legal and Customs Departments. Chaim holds Master of Business Administration (MBA; major in Finance) and BA in Accounting & Economics from the Bar Ilan University, Israel. He also holds Israeli Certified Public Accountant (iCPA).

Board of Directors

Dr. Robert Heft brings more than 30 years of biopharmaceutical executive leadership experience to Eloxx. Dr. Heft served as President, Chief Executive Officer, and member of the Board of Directors of Enobia Pharma Inc. (Montreal, Quebec) from 2005-2012. In February 2012, Dr Heft sold Enobia to Alexion Pharmaceuticals Inc. for USD 1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. He has also held several senior positions with BioMarin Pharmaceutical Inc. (Novato, California) after selling the pharmaceutical assets of IBEX Pharmaceuticals Inc. (IBT:TSX, Montreal, Quebec) to BioMarin in 2001. Dr Heft founded IBEX in 1986, and served as its President, Chief Scientist and member of its Board of Directors until 2001. He also served as Executive in Residence at Sectoral Asset Management as well as on the Board of Directors of BioCapital (Private Equity/Venture Capital), the Canadian Genetic Diseases Network and the Industrial Biotechnology Association of Canada. In addition to Eloxx, Dr. Heft currently serves on the boards of Zingenix Ltd., VisionGate Inc., Lumos Pharma Inc., Clementia Pharmaceuticals Inc., and Ra Pharma Inc. He also serves on the Advisory Board of Sectoral Asset Management.

Dr Heft obtained his PhD from the Massachusetts Institute of Technology in Genetic Engineering/Radiological Sciences in 1986 and was a Neurology Fellow at the Massachusetts General Hospital. Prior to that, he received a Masters degree in Nuclear Engineering from Cornell University and a Bachelor of Mechanical Engineering from McGill University. Dr Heft has published and been awarded several patents in the fields of coagulation, phenylketonuria and hypophosphatasia. He has also received several awards for his work including: Company of the Year (2012 Gold Leaf Award for Enobia Pharma) from BIOTECanada, Entrepreneur of the Year (Canada 2012) from the Canadian Venture Capital Association, and the Genesis Award (2012) from BioQuebec.

Dr. Silvia Noiman has over 20 years of experience as an entrepreneur and executive in the biopharmaceuticals industry, including serving as venture partner at Pontifax Venture Capital. Dr. Noiman founded and served as Executive Chairwoman of many of the Pontifax VC portfolio companies, including cCAM Biotherapeutics Ltd, acquired by Merck (NYSE:MRK) in 2015 and Quiet Therapeutics Ltd. She was also founder and Senior Vice President of Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a $500M publicly traded multi-product company (NASDAQ, EPIX). Under Dr. Noiman’s leadership, the company progressed four discovery programs to late stage clinical trials and formed significant big pharma partnerships. Prior to founding Predix, she was engaged in large-scale entrepreneurial activities in the biotech industry in Israel. Dr. Noiman holds a PhD in Molecular Biology from Tel Aviv University and did a post-doc at the Weizmann Institute of Science. Dr. Noiman has published numerous papers and holds several patents.

Mr. Veinrib has extensive managerial experience in the internet, digital, and communication fields. He worked as a VP at Elron, as well as serving as Executive Assistant to the President and CEO at Discount Investment Corporation (DIC). Mr. Veinrib previously served as director of NetVision and Nana10 as well as other companies within the DIC group. Mr. Veinrib holds a B.A. in Economics from Tel Aviv University.

Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, which established 3 funds with over $220 million under management and over 30 portfolio companies. Over the past 10 years’, Mr. Nussbaum has been managing The Pontifax Group’s activity together with Tomer Kariv. From 2006 to 2008 he also served as CEO of Biomedix Ltd. and Spearhead Ltd., and was Chairman of the Board of Nasvax Ltd. Mr. Nussbaum’s experience in the life sciences arena coupled with 10 years’ experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. Mr. Nussbaum also serves on the Boards of Directors of many of The Pontifax Group’s portfolio companies, including Kite Pharma Inc. (public co.), Insuline Ltd. (public co.), BioBlast (public co.), UroGen Pharma (formerly, TheraCoat; public co.), CollPlant (public), ProTab, Quiet, and Fusimab Ltd, and as Ocon Chairman of the Board.

Tomer is the co-founder and Chief Executive Officer of Pontifax – The fund is running more than 45 portfolio companies around the globe and serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as the Chairman of Check-Cap and is a board member at Macrocure and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management positions at top Israeli financial institutions, playing a key role in investing in, nurturing and managing technology driven startups. Tomer holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.